Page last updated: 2024-10-25

cisapride and Cardiac Arrest, Sudden

cisapride has been researched along with Cardiac Arrest, Sudden in 5 studies

Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.

Research Excerpts

ExcerptRelevanceReference
"Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride."8.81Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. ( Barbey, JT; Lazzara, R; Zipes, DP, 2002)
"We aimed to examine the association between cisapride and ventricular arrhythmia, and examine the relationship to dose and CYP3A4 inhibitors."7.74Cisapride and ventricular arrhythmia. ( Bilker, WB; Hennessy, S; Kimmel, SE; Leonard, CE; Newcomb, C, 2008)
"Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride."4.81Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. ( Barbey, JT; Lazzara, R; Zipes, DP, 2002)
"We aimed to examine the association between cisapride and ventricular arrhythmia, and examine the relationship to dose and CYP3A4 inhibitors."3.74Cisapride and ventricular arrhythmia. ( Bilker, WB; Hennessy, S; Kimmel, SE; Leonard, CE; Newcomb, C, 2008)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Healy, D1
Howe, G1
Mangin, D1
Le Noury, J1
Hennessy, S2
Leonard, CE2
Palumbo, CM1
Bilker, WB2
Newcomb, C2
Kimmel, SE2
Erickson, CC1
Jones, CS1
Barbey, JT1
Lazzara, R1
Zipes, DP1

Reviews

1 review available for cisapride and Cardiac Arrest, Sudden

ArticleYear
Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride.
    Journal of cardiovascular pharmacology and therapeutics, 2002, Volume: 7, Issue:2

    Topics: Arrhythmias, Cardiac; Cisapride; Death, Sudden, Cardiac; Gastrointestinal Agents; Humans; Long QT Sy

2002

Other Studies

4 other studies available for cisapride and Cardiac Arrest, Sudden

ArticleYear
Sudden cardiac death & the Reverse Dodo Verdict.
    The International journal of risk & safety in medicine, 2014, Volume: 26, Issue:2

    Topics: Antipsychotic Agents; Cisapride; Death, Sudden, Cardiac; Drug-Related Side Effects and Adverse React

2014
Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database.
    Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:12

    Topics: Arrhythmias, Cardiac; Cisapride; Cohort Studies; Databases, Factual; Death, Sudden, Cardiac; Domperi

2008
Cisapride and ventricular arrhythmia.
    British journal of clinical pharmacology, 2008, Volume: 66, Issue:3

    Topics: Adult; Aged; Arrhythmias, Cardiac; Case-Control Studies; Cisapride; Cytochrome P-450 CYP3A; Death, S

2008
Pediatric sudden cardiac death: what the pediatrician needs to know.
    Pediatric annals, 2000, Volume: 29, Issue:8

    Topics: Child; Cisapride; Contraindications; Death, Sudden, Cardiac; Gastrointestinal Agents; Humans; Risk F

2000